Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 52,317 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $6.85, for a total transaction of $358,371.45. Following the completion of the sale, the director directly owned 2,783,781 shares of the company’s stock, valued at approximately $19,068,899.85. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.00, for a total transaction of $647,108.00.
• On Thursday, August 6th, Kush Parmar sold 10,494 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total transaction of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Performance

TRDA stock opened at $7.67 on Thursday. Entrada Therapeutics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $16.45. The company has a market capitalization of $298.67 million, a price-to-earnings ratio of -1.94 and a beta of -0.26. The business’s 50 day moving average price is $6.89 and its two-hundred day moving average price is $9.62.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Sell-side analysts forecast that Entrada Therapeutics, Inc. will post -4.04 earnings per share for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds have recently added to or reduced their stakes in TRDA. Baker BROS. Advisors LP grew its stake in shares of Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Entrada Therapeutics in the 2nd quarter worth about $19,013,000. Wellington Management Group LLP raised its position in shares of Entrada Therapeutics by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the last quarter. Millennium Management LLC boosted its stake in Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after purchasing an additional 666,287 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after purchasing an additional 42,479 shares in the last quarter. 86.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TRDA. Guggenheim dropped their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $4.19 from $4.33 and its FY2027 estimate to a loss of $3.13 from $3.14. The improved longer-term forecasts may be helping sentiment, although the firm maintained a Neutral rating.
• Neutral Sentiment: HC Wainwright slightly worsened its estimates for the third and fourth quarters of 2026, forecasting losses of $1.18 and $1.04 per share, respectively. The revisions suggest continued heavy spending and ongoing losses, with the firm’s full-year FY2026 estimate still below the current consensus loss estimate of $4.07 per share.
• Neutral Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock established a new position, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These institutional purchases may provide some support, although the reported transaction periods are inconsistent and should be interpreted cautiously.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold 62,811 shares for approximately $431,829 across August 6 and 7. Director Kush Parmar also sold 155,255 shares for roughly $1.08 million from August 6 through 10. The sales reduced their respective holdings but did not represent complete exits, as both continued to own substantial positions. SEC insider transaction filings
• Negative Sentiment: Entrada’s latest quarterly results were weaker than expected: the company reported a $1.01-per-share loss versus the $0.97 consensus estimate and revenue of $0.90 million versus expectations of $2.32 million. As a clinical-stage biotechnology company, TRDA remains dependent on pipeline progress and future financing rather than current operating profits.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.